Efficacy and safety of transarterial chemoembolization plus lenvatinib with or without programmed death-1 inhibitors in the treatment of unresectable hepatocellular carcinoma: a systematic review and meta-analysis-Reference-Cited by-同舟云学术

Efficacy and safety of transarterial chemoembolization plus lenvatinib with or without programmed death-1 inhibitors in the treatment of unresectable hepatocellular carcinoma: a systematic review and meta-analysis

Published:2023-08-11 Issue:15 Volume:149 Page:14451-14461
ISSN:0171-5216
Container-title:Journal of Cancer Research and Clinical Oncology
language:en
Short-container-title:J Cancer Res Clin Oncol

Author:

Liu Junning,Wei Song,Yang Linfeng,Yu Jiahui,Yan Duan,Yi Pengsheng

Funder

Bureau of Science and Technology Nanchong City

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00432-023-05231-x.pdf

Reference44 articles.

1. Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J et al (2011) GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 64(4):401–406. https://doi.org/10.1016/j.jclinepi.2010.07.015

2. Cai M, Huang W, Huang J, Shi W, Guo Y, Liang L et al (2022) Transarterial chemoembolization combined with lenvatinib plus PD-1 inhibitor for advanced hepatocellular carcinoma: a retrospective cohort study. Front Immunol. https://doi.org/10.3389/fimmu.2022.848387

3. Chen S, Wu Z, Shi F, Mai Q, Wang L, Wang F et al (2022). Lenvatinib plus TACE with or without pembrolizumab for the treatment of initially unresectable hepatocellular carcinoma harbouring PD-L1 expression: a retrospective study. J Cancer Res Clin Oncol 148(8):2115–2125. https://doi.org/10.1007/s00432-021-03767-4

4. Finn RS, Ikeda M, Zhu AX, Sung MW, Baron AD, Kudo M et al (2020a) Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol 38(26):2960–2970. https://doi.org/10.1200/jco.20.00808

5. Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY et al (2020b) Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 382(20):1894–1905. https://doi.org/10.1056/NEJMoa1915745

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of TACE combined with tyrosine kinase inhibitors and camrelizumab for unresectable hepatocellular carcinoma: A systematic review and meta‑analysis;Oncology Letters;2024-06-26

2. Lenvatinib in combination with transarterial chemoembolization vs. sorafenib in combination with transarterial chemoembolization for unresectable hepatocellular carcinoma: A network meta‑analysis;Oncology Letters;2024-06-03